What's new?

Sofinnova Partners Announces Third Investment from its Italian Fund

This investment brings the total financing by Sofinnova Partners to €25 million over the past six months   MILAN, Italy – April 20, 2020 – Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today an investment in Genespire, a Milan-based gene-therap...

Henrijette Richter appointed Managing Partner of Sofinnova Partners

BioAmber Signs Its First Succinic Acid Take-­‐or-­‐Pay Contract Contract with PTT-­‐MCC Biochem, a joint venture between Mitsubishi Chemical and PTT PCL

• Contract guarantees sales volume for Sarnia plant during its first three years ofoperation • Agreement ensures BioAmberis the principal supplier to a key emerging buyer of succinic acid • PTTMCC selection of BioAmber as supplier validates bio-­‐succinic cost competitiveness and quality

Plus de 1 00 00 patients ont bénéficié de la technologie auto¬apposante de STENTYS

Paris, le 15 septembre 2011 : STENTYS (FR0010949404 – STNT), société de technologie médicale qui commercialise le premier et le seul stent auto¬apposant pour le traitement de l’infarctus du myocarde, annonce aujourd’hui que son stent autoapposant a été implanté dans plus de 1 000 patients dans le monde.

Inside's ICAO-Lite platform open doors for TIL Technologies

First Commercial ICAO-Lite Deployment Provides Secure, Intelligent Credentials for both Access Control and Identity

1